Current stock page

Financial Data

OGN Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareDrug Manufacturers - GeneralScore data as of Oct 21, 2026

OGNOrganon & Co.

Healthcare / Drug Manufacturers - General

Relative Leader / Watch

Strong Relative Position

NeutralEdge 9/10
$13.75−$0.01 (−0.07%)

Latest quote

  • Momentum
    67
  • Value
    75
  • Quality
    47
  • Risk resilience
    70
  • Sentiment
    —
algovestiq.comScore data as of Oct 21, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
3
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Oct 22, 2026.

Income statement
3 periods
Metric2026-06-302026-03-312025-12-31
Revenue$1.56B$1.46B$1.51B
Gross Profit$847M$783M$759M
Operating Income$323M$266M$235M
Net Income$108M$146M-$205M
EPS$0.41$0.55-$0.79
Cash flow statement
3 periods
Metric2026-06-302026-03-312025-12-31
Operating Cash Flow$107M$225M$141M
Capital Expenditure-$42M-$37M-$45M
Free Cash Flow$65M$188M$96M
Net Cash Provided By Operating Activities$107M$225M$141M
Balance sheet
3 periods
Metric2026-06-302026-03-312025-12-31
Total Assets$13.18B$13B$0
Total Debt$8.55B$8.57B$10.6B
Cash And Cash Equivalents———
Total Liabilities$12.17B$12.09B-$906M
Total Stockholders Equity$1.01B$903M$906M
Key financial metrics
3 periods
Metric2026-06-302026-03-312025-12-31
P/E ratio8.262.72-2.27
P/B ratio3.531.732.48
P/S ratio2.281.071.24
Debt To Equity8.59.4911.7
Free Cash Flow Yield1.83%12.05%5.15%
Financial ratios
3 periods
Metric2026-06-302026-03-312025-12-31
P/E ratio8.262.72-2.27
P/B ratio3.531.732.48
P/S ratio2.281.071.24
Return On Equity10.74%16.17%-27.26%
Debt To Equity8.59.4911.7

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe17.42x
Pb3.59x
Gross Margin52.98%
Operating Margin19.29%
ROE23.44%
ROIC4.73%
Debt To Equity8.5
FCF Yield13.78%

As of Oct 21, 2026

Technical indicators
MetricValue
Close$13.75
Volume2.56M
RSI (14)55.88
MACD0.02
MACD signal0.02
MACD histogram-0
ADX (14)23.66
SMA (50)$13.73
SMA (200)$11.32
ATR (14)$0.04
Historical volatility (annualized)3.24%
Volume (20-day average)2.22M

As of Oct 21, 2026

Risk measures
MetricValue
Resilience score70/100
Beta1.54
Annual volatility66.65%
Max Drawdown-41.60%
Sharpe Ratio0.86
VaR (95%, 1-day)-4.01%

As of Oct 21, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

OGN Financial Data FAQ

What is Organon & Co.'s revenue?

Organon & Co.'s revenue is one of the core financial data points for OGN. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Organon & Co.'s revenue growing?

Revenue growth shows whether Organon & Co. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is OGN's EPS?

OGN's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Organon & Co.'s net income?

Organon & Co.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Organon & Co. generate?

Free cash flow shows how much cash Organon & Co. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Organon & Co. have?

Cash and debt help frame OGN's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.